Transforming growth factor-beta and the kidney: What we know and what we can do?

Hai Chun Yang, Yiqin Zuo, Agnes B. Fogo

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Transforming growth factor-β (TGF-β) and its receptors are expressed in the kidney. The effects of TGF-β are mainly through activation of Smad pathways. In different pathophysiological situations such as development, immunomodulation, fibrosis and cell response, TGF-ββ interacts with other factors including angiotensin II, plasminogen activator inhibitor-1, connective tissue growth factor, integrins, and thymosin β4. Clinical studies have shown that specific polymorphisms of TGF-β genes and increased serum, urine and biopsied specimen levels are associated with human renal diseases. However, the effects of inhibition of TGF-β system are complex, depending on the injury type, disease stage and dosage of the inhibitor. Several animal studies have shown beneficial effects anti-TGF-β especially in chronic renal diseases, while data from clinical studies are still limited. In this review, current knowledge about the role of TGF-β system in the kidney and potential of strategies to modulate TGF-β for renoprotection are discussed.

Original languageEnglish (US)
Pages (from-to)87-96
Number of pages10
JournalCurrent Enzyme Inhibition
Issue number2
StatePublished - Jul 2010
Externally publishedYes


  • Fibrosis
  • Kidney
  • TGF-β

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of 'Transforming growth factor-beta and the kidney: What we know and what we can do?'. Together they form a unique fingerprint.

Cite this